Patents by Inventor Pavel Kamaev
Pavel Kamaev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11892739Abstract: A method for making electrophoretic displays layers including various thin films that are deposited directly onto a layer of microcapsules of electrophoretic media. In an embodiment, a thin film of a light-transmissive conductive material is deposited to create a clear front electrode for an electrophoretic display. In some embodiments, both a dielectric layer and a thin film of a light-transmissive conductive material will be deposited onto the microcapsules.Type: GrantFiled: February 4, 2021Date of Patent: February 6, 2024Assignee: E Ink CorporationInventors: Nishit Murari, Pavel Kamaev, David Darrell Miller, Richard J. Paolini, Jr., Jay William Anseth
-
Publication number: 20230129652Abstract: Example eye treatments detennine an area at a surface of a cornea for delivery of a cross-linking agent. The example treatments disrupt tissue at the area at the surface of the con1ea up to a depth corresponding to apical layers of superficial squamous cells of the cornea, e.g., no greater than approximately 10 ?m to approximately 15 lm. The example treatments apply a cross-linking agent to the area at the surface of the cornea. The cross-linking agent is transmitted through the disrupted area at a greater rate relative to non disrupted areas of the cornea. The example treatments deliver photoactivating light to the cornea. The photoactivating light activates the cross-linking agent to generate cross-linking activity in the cornea.Type: ApplicationFiled: August 8, 2022Publication date: April 27, 2023Inventors: Marc D. Friedman, Alexandra Nicklin, Pavel Kamaev
-
Patent number: 11406805Abstract: Example eye treatments determine an area at a surface of a cornea for delivery of a cross-linking agent. The example treatments disrupt tissue at the area at the surface of the cornea up to a depth corresponding to apical layers of superficial squamous cells of the cornea, e.g., no greater than approximately 10 ?m to approximately 15 ?m. The example treatments apply a cross-linking agent to the area at the surface of the cornea. The cross-linking agent is transmitted through the disrupted area at a greater rate relative to non disrupted areas of the cornea. The example treatments deliver photoactivating light to the cornea. The photoactivating light activates the cross-linking agent to generate cross-linking activity in the cornea.Type: GrantFiled: August 8, 2017Date of Patent: August 9, 2022Assignee: AVEDRO, INC.Inventors: Marc D. Friedman, Alexandra Nicklin, Pavel Kamaev
-
Publication number: 20220151830Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.Type: ApplicationFiled: October 25, 2021Publication date: May 19, 2022Inventors: Marc D. Friedman, Pavel Kamaev, Mikhail Smirnov
-
Publication number: 20220152202Abstract: A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.Type: ApplicationFiled: October 25, 2021Publication date: May 19, 2022Inventors: Pavel Kamaev, Marc D. Friedman
-
Publication number: 20220054858Abstract: An antimicrobial treatment system comprises a wearable photoactivation device. The wearable photoactivation device includes a body configured to be positioned on a head of a subject over one or more eyes of the subject. The body includes one or more windows or openings that allow the one or more eyes to see through the body. The body includes one or more photoactivating light sources coupled to the body and configured to direct photoactivating light to the one or more eyes according to illumination parameters. The illumination parameters determine a dose of the photoactivating light that activates, according to photochemical kinetic reactions, a photosensitizer applied to the one or more eyes and generates reactive oxygen species that provide an antimicrobial effect in the one or more eyes, without substantially inducing cross-linking activity that produces biomechanical changes in the one or more eyes.Type: ApplicationFiled: November 8, 2021Publication date: February 24, 2022Inventors: Marc D. Friedman, Mikhail Smirnov, Pavel Kamaev
-
Publication number: 20220041563Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.Type: ApplicationFiled: December 4, 2019Publication date: February 10, 2022Inventors: Jason Hill, Desmond Adler, Marc D. Friedman, Pavel Kamaev, Evan Sherr
-
Patent number: 11219553Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.Type: GrantFiled: July 15, 2019Date of Patent: January 11, 2022Assignee: Avedro, Inc.Inventors: Marc D. Friedman, Pavel Kamaev, Mikhail Smirnov
-
Patent number: 11207410Abstract: A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.Type: GrantFiled: July 21, 2016Date of Patent: December 28, 2021Assignee: Avedro, Inc.Inventors: Pavel Kamaev, Marc D. Friedman
-
Patent number: 11167149Abstract: An antimicrobial treatment system comprises a wearable photoactivation device. The wearable photoactivation device includes a body configured to be positioned on a head of a subject over one or more eyes of the subject. The body includes one or more windows or openings that allow the one or more eyes to see through the body. The body includes one or more photoactivating light sources coupled to the body and configured to direct photoactivating light to the one or more eyes according to illumination parameters. The illumination parameters determine a dose of the photoactivating light that activates, according to photochemical kinetic reactions, a photosensitizer applied to the one or more eyes and generates reactive oxygen species that provide an antimicrobial effect in the one or more eyes, without substantially inducing cross-linking activity that produces biomechanical changes in the one or more eyes.Type: GrantFiled: April 15, 2019Date of Patent: November 9, 2021Assignee: Avedro, Inc.Inventors: Marc D. Friedman, Mikhail Smirnov, Pavel Kamaev
-
Patent number: 11154618Abstract: A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.Type: GrantFiled: July 21, 2016Date of Patent: October 26, 2021Assignee: Avedro, Inc.Inventors: Pavel Kamaev, Marc D. Friedman
-
Patent number: 11154423Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.Type: GrantFiled: July 15, 2019Date of Patent: October 26, 2021Assignee: Avedro, Inc.Inventors: Marc D. Friedman, Pavel Kamaev, Mikhail Smirnov
-
Publication number: 20210247656Abstract: A method for making electrophoretic displays layers including various thin films that are deposited directly onto a layer of microcapsules of electrophoretic media. In an embodiment, a thin film of a light-transmissive conductive material is deposited to create a clear front electrode for an electrophoretic display. In some embodiments, both a dielectric layer and a thin film of a light-transmissive conductive material will be deposited onto the microcapsules.Type: ApplicationFiled: February 4, 2021Publication date: August 12, 2021Inventors: Nishit MURARI, Pavel KAMAEV, David Darrell MILLER, Richard J. PAOLINI, JR., Jay William ANSETH
-
Publication number: 20210101020Abstract: Devices and approaches for activating cross-linking within corneal tissue to stabilize and strengthen the corneal tissue following an eye therapy treatment. A feedback system is provided to acquire measurements and pass feedback information to a controller. The feedback system may include an interferometer system, a corneal polarimetry system, or other configurations for monitoring cross-linking activity within the cornea. The controller is adapted to analyze the feedback information and adjust treatment to the eye based on the information. Aspects of the feedback system may also be used to monitor and diagnose features of the eye. Methods of activating cross-linking according to information provided by a feedback system in order to improve accuracy and safety of a cross-linking therapy are also provided.Type: ApplicationFiled: December 15, 2020Publication date: April 8, 2021Inventors: David Muller, John Marshall, Marc D. Friedman, Stephen Blinn, Ronald Scharf, Pavel Kamaev, Radha Pertaub
-
Publication number: 20200345847Abstract: Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine.Type: ApplicationFiled: July 20, 2020Publication date: November 5, 2020Inventors: Marc D. Friedman, Pavel Kamaev, Martin Joseph Coffee, Rajesh K. Rajpal, Alexandra Nicklin
-
Publication number: 20200046835Abstract: Systems, methods, and compositions generate cross-linking activity for treatment of eye disorders. Various agents, additives, buffers, etc., may be employed in formulations with a cross-linking agent to enhance treatment. For example, a composition for applying treatment to a cornea of an eye includes a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photo-activating light. The composition also includes an iron additive and citrate buffer. In some cases, the cross-linking agent may include riboflavin. In other cases, the iron additive may include FeSO4. In further cases, the iron additive may be dissolved in the citrate buffer.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Inventors: Pavel Kamaev, Marc Friedman, Evan Sherr, Sarah M. Peterson, David Muller
-
Publication number: 20190365564Abstract: Devices and approaches for activating cross-linking within corneal tissue to stabilize and strengthen the corneal tissue following an eye therapy treatment. A feedback system is provided to acquire measurements and pass feedback information to a controller. The feedback system may include an interferometer system, a corneal polarimetry system, or other configurations for monitoring cross-linking activity within the cornea. The controller is adapted to analyze the feedback information and adjust treatment to the eye based on the information. Aspects of the feedback system may also be used to monitor and diagnose features of the eye. Methods of activating cross-linking according to information provided by a feedback system in order to improve accuracy and safety of a cross-linking therapy are also provided.Type: ApplicationFiled: May 17, 2019Publication date: December 5, 2019Inventors: David Muller, John Marshall, Marc D. Friedman, Stephen Blinn, Ronald Scharf, Pavel Kamaev, Radha Pertaub
-
Publication number: 20190336336Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.Type: ApplicationFiled: July 15, 2019Publication date: November 7, 2019Inventors: Marc D. Friedman, Pavel Kamaev, Mikhail Smirnov
-
Publication number: 20190240503Abstract: An antimicrobial treatment system comprises a wearable photoactivation device. The wearable photoactivation device includes a body configured to be positioned on a head of a subject over one or more eyes of the subject. The body includes one or more windows or openings that allow the one or more eyes to see through the body. The body includes one or more photoactivating light sources coupled to the body and configured to direct photoactivating light to the one or more eyes according to illumination parameters. The illumination parameters determine a dose of the photoactivating light that activates, according to photochemical kinetic reactions, a photosensitizer applied to the one or more eyes and generates reactive oxygen species that provide an antimicrobial effect in the one or more eyes, without substantially inducing cross-linking activity that produces biomechanical changes in the one or more eyes.Type: ApplicationFiled: April 15, 2019Publication date: August 8, 2019Inventors: Marc D. Friedman, Mikhail Smirnov, Pavel Kamaev
-
Patent number: 10350111Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.Type: GrantFiled: April 27, 2016Date of Patent: July 16, 2019Assignee: Avedro, Inc.Inventors: Marc D. Friedman, Pavel Kamaev, Mikhail Smirnov